## [What Are the 4 Key Shifts in China’s Pharma—and Why You Need to Know?](/what-are-the-4-key-shifts-in-chinas-pharma-and-why-you-need-to-know) 2 min read Your browser does not support the audio element. China continues to reshape its pharmaceutical Regulatory landscape through modernization, digitalization, and global alignment. In a recent set of major announcements by the **National Medical Products Administration (NMPA)**, significant changes were introduced, ranging from the expansion of **eCTD submissions**, the release of the **2025 edition of the Chinese Pharmacopoeia**, to the approval of several high-priority innovative drugs. Together, these reforms are more than policy updates—they are a signal of how pharmaceutical engagement in China is evolving at both strategic and operational levels. ## 1. eCTD Scope Expansion Through **Announcement No. 10**, released on **Jan 23, 2025**, the NMPA expanded the use of the **electronic Common Technical Document (eCTD)** to cover additional application types, starting **January 27, 2025**. The scope now includes: - **Clinical Trial Applications (CTAs)** for chemical drugs (Classes 1–5) - **Marketing Authorization Applications (MAAs)** for chemical drugs (Classes 2, 3, 4, and 5.2) - **CTAs** for biological products (Classes 1–3) - **MAAs** for preventive biological products and biological products (Classes 2 and 3) **Why This Matters:** - **Faster and more efficient submissions**: Streamlined documentation and automation reduce approval timelines. - **Improved traceability and lifecycle tracking**: Structured formats make Regulatory oversight more robust. - **Global alignment**: Adopting eCTD brings China in line with ICH, FDA, and EMA Regulatory systems. ## 2. Chinese Pharmacopoeia Update The **2025 edition of the Pharmacopoeia of the People’s Republic of China** was formally issued on **Mar 20, 2025**, and will take effect starting **October 1, 2025**. The update was jointly released by the NMPA and the National Health Commission through **Announcement No. 29**. **Key Enhancements:** - Updates across **chemical drugs, biologics, and Traditional Chinese Medicine (TCM)** - Enhanced **analytical methods** and **testing standards** - Tighter **quality control protocols** for manufacturing and post-approval monitoring For global pharmaceutical companies, the update underscores the need for **method validation, analytical consistency**, and **GMP-aligned manufacturing documentation**. ## 3. New Drug Approvals Reflect Strategic Focus In 2025, new drug approvals in China, particularly by the National Medical Products Administration (NMPA), are reflecting a strategic focus on addressing specific disease areas and embracing Regulatory advancements. The focus areas include oncology, hematology, and infectiology, with a growing emphasis on innovative therapies for unmet medical needs like rare diseases and pediatric populations. Regulatory reforms, including the acceptance of real-world evidence and priority review pathways, are accelerating the approval process for these high-impact therapies. ## 4. Focus on Quality Oversight On **June 9, 2025**, the NMPA convened its annual **Quality Management System (QMS) review**, focusing on 2024 performance outcomes in pharmaceutical manufacturing. The review addressed: - Identifying the deficiencies and CAPAs, as well as the recommendations for improvement. - Deepening the effective operation of vaccine QMS, coordinate and promote the smooth start of pharmaceutical QMS. - Enhance the capacity of pharmaceutical inspection,  adhere to the whole-process management. - In line with international standards, promote the improvement of drug Regulatory capabilities through a sound Regulatory quality system. The outcomes of this review are expected to shape upcoming guidance documents and deepen **compliance expectations** across the pharmaceutical sector. ## Why This Matters for Pharmaceutical Companies As the world’s second-largest pharmaceutical market, China is no longer just a commercial destination—it’s becoming a **Regulatory leader**. These recent reforms highlight four critical shifts: 1. **Digital-by-default operations**: With expanded eCTD mandates, companies must modernize their submission infrastructure. 2. **Higher quality benchmarks**: Pharmacopoeial updates demand tighter control of analytical and manufacturing processes. 3. **Accelerated innovation**: Accelerated pathways are becoming more accessible for both local and global firms. 4. **Enforcement-driven QMS culture**: Proactive preparedness is essential to navigate evolving GMP and post-market surveillance standards. Companies aiming to succeed in China must now balance **compliance readiness, strategic agility**, and **local-market adaptation**. **Looking to align with China's new Regulatory direction?** [Get in touch](https://www.freyrsolutions.com.cn/) with Freyr’s global Regulatory experts today and stay compliant, competitive, and future-ready.